Fig. 3: Overall survival by JAK mutation status. | Nature Communications

Fig. 3: Overall survival by JAK mutation status.

From: Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

Fig. 3: Overall survival by JAK mutation status.The alternative text for this image may have been generated using AI.

Kaplan–Meier survival curves for patients with wild type JAK1/2 (blue) and deleterious mutations in JAK1/2 (green) are shown, in Arm A (targeted therapy followed by immunotherapy), Arm B (immunotherapy followed by targeted therapy), and Arm C (a course of targeted therapy preceding immunotherapy and targeted therapy) of SECOMBIT. Dotted lines represent 95% confidence intervals. Source data are provided as a Source Data file.

Back to article page